Minze Health NV closed on $4.1 million of seed funding to develop its digital solution for the treatment of urinary tract problems. Three major Belgian funds participated in this seed round, led by White Fund SA, a private equity fund focusing on med-tech. Capricorn Partners NV joined White Fund via its Digital Growth fund, alongside Flemish investment company PMV NV.

Vevo Therapeutics Inc. raised $12 million in an over-subscribed seed round to build out an in vivo single-cell screening platform, which will enable it to interrogate simultaneously the effects of small molecule drug leads on multiple cancer cell lines.

Apogee Therapeutics Inc. emerged from stealth with $169 million in financing and a pipeline of four preclinical antibody development programs that take aim at major immunological and inflammatory disorders.

Wangli Technology, a subsidiary of Adai Technology (Beijing) Co. Ltd., has raised ¥100 million (US$14 million) to continue developing digital therapeutics aimed at mental health indications.

Biopharma financings are tracking only 3% below 2019’s full-year total, but the volume of activity is at its lowest point since 2017. With a total of $56.1 billion raised, 2022 is currently the sixth best financing year on record, but it is significantly behind some of the years that rank higher.

Vega Therapeutics Inc. emerged from stealth in advance of a podium presentation at this year’s American Society of Hematology meeting in New Orleans. The company, a spin-out from Star Therapeutics Inc., will disclose preclinical data on its lead drug candidate VGA-039, a first-in-class antibody in development for von Willebrand disease.